Positive expression of chemokine (C-C Motif) ligand 18 and prognosis in cancer: A meta-analysis

Positive expression of chemokine (C-C Motif) ligand 18 and prognosis in cancer: A meta-analysis

Chemokine (C-C Motif) Ligand 18 (CCL18) is a chemotactic cytokine involved in the pathogenesis and progression of various cancers by activating downstream signaling pathways and affecting cellular behaviors. We conducted a meta-analysis to evaluate the CCL18 as a prognostic marker for cancer and det...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of B.U. ON. 2018-07, Vol.23 (4), p.1185-1194
Hauptverfasser: Huang, Hui, Li, Jing, Hu, Wen-Jia, Chen, Mei-Hui, Chen, Sha-Sha, Chen, Chen, Luo, Hai-Qing, Zhou, Ke-Yuan, Liu, Xin-Guang, Li, Xiang-Yong
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1194
container_issue 4
container_start_page 1185
container_title Journal of B.U. ON.
container_volume 23
creator Huang, Hui
Li, Jing
Hu, Wen-Jia
Chen, Mei-Hui
Chen, Sha-Sha
Chen, Chen
Luo, Hai-Qing
Zhou, Ke-Yuan
Liu, Xin-Guang
Li, Xiang-Yong
description Chemokine (C-C Motif) Ligand 18 (CCL18) is a chemotactic cytokine involved in the pathogenesis and progression of various cancers by activating downstream signaling pathways and affecting cellular behaviors. We conducted a meta-analysis to evaluate the CCL18 as a prognostic marker for cancer and determine the relationship between CCL18 and clinicopathological features of cancer. We searched the PubMed, Cochrane, Embase, Web of Science and SinoMed databases for publications to investigate the association between CCL18 expression and survival outcome in cancer. Hazard ratios (HRs) and 95% confidence intervals (CI) of overall survival (OS) were pooled. Odds ratios (ORs) of clinicopathological features were computed. Meta-analysis was performed using STATA 12.0 software. Our meta-analysis identified a total of 17 studies including 2829 cases. Meta-analysis revealed that the expression of CCL18 in various cancer tissues was significantly higher than that in the normal group (OR=16.694, 95% CI=14.117-27.476, p
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_2125298948</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2125298948</sourcerecordid><originalsourceid>FETCH-LOGICAL-p211t-e612b97ffda26b867b8b13ffaf2f9b1fdc5800ad0e1a8206c00a2ed18e2592063</originalsourceid><addsrcrecordid>eNo1kEtPwzAQhH0A0ar0LyAfyyGS7RDH5lZFvKQiOMA58mNdDIkd4gTRf48RZS-j0Xy7Ws0JWlJK6oJwVi3QOqV3kocTyqU4Q4uSlJVgJVmi9jkmP_kvwPA9jJCSjwFHh80b9PHDB8CbpmjwY5y8u8Sd36tgMRX4V4Yx7kNeT9gHbFQwMF7jLe5hUoUKqjvk6BydOtUlWB91hV5vb16a-2L3dPfQbHfFwCidCuCUaVk7ZxXjWvBaC01L55RjTmrqrKkEIcoSoEowwk02DCwVwCqZfblCm7-7-anPGdLU9j4Z6DoVIM6pZZRVTAp5JTJ6cURn3YNth9H3ajy0_6WUPy9jXLY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2125298948</pqid></control><display><type>article</type><title>Positive expression of chemokine (C-C Motif) ligand 18 and prognosis in cancer: A meta-analysis</title><source>EZB-FREE-00999 freely available EZB journals</source><creator>Huang, Hui ; Li, Jing ; Hu, Wen-Jia ; Chen, Mei-Hui ; Chen, Sha-Sha ; Chen, Chen ; Luo, Hai-Qing ; Zhou, Ke-Yuan ; Liu, Xin-Guang ; Li, Xiang-Yong</creator><creatorcontrib>Huang, Hui ; Li, Jing ; Hu, Wen-Jia ; Chen, Mei-Hui ; Chen, Sha-Sha ; Chen, Chen ; Luo, Hai-Qing ; Zhou, Ke-Yuan ; Liu, Xin-Guang ; Li, Xiang-Yong</creatorcontrib><description>Chemokine (C-C Motif) Ligand 18 (CCL18) is a chemotactic cytokine involved in the pathogenesis and progression of various cancers by activating downstream signaling pathways and affecting cellular behaviors. We conducted a meta-analysis to evaluate the CCL18 as a prognostic marker for cancer and determine the relationship between CCL18 and clinicopathological features of cancer. We searched the PubMed, Cochrane, Embase, Web of Science and SinoMed databases for publications to investigate the association between CCL18 expression and survival outcome in cancer. Hazard ratios (HRs) and 95% confidence intervals (CI) of overall survival (OS) were pooled. Odds ratios (ORs) of clinicopathological features were computed. Meta-analysis was performed using STATA 12.0 software. Our meta-analysis identified a total of 17 studies including 2829 cases. Meta-analysis revealed that the expression of CCL18 in various cancer tissues was significantly higher than that in the normal group (OR=16.694, 95% CI=14.117-27.476, p&lt;0.01, random effects). The abnormal expression of CCL18 was associated with lymph node metastasis (OR=4.409, 95% CI=2.129-9.128, p&lt;0.01, random effects) and TNM stage (breast cancer subgroup: III+IV vs I+II OR=13.187, 95% CI=8.417-20.660, p&lt;0.01; gastric cancer subgroup: III+IV vs I+II OR=0.034, 95% CI=0.008-0.137, p&lt;0.01) but is was not related to gender (male vs. female: OR=0.88, 95% CI=0.667-1.162, p=0.368) and age (&gt;60 vs. ≤60 years: OR=1.118, 95% CI=0.795-1.571, p-0.522). CCL18 overexpression was associated with poor overall prognosis of breast cancer (Hazard Ratio/HR=2.969, 95% CI=1.361- 6.478, p&lt;0.01, random effects). CCL18 is highly expressed in cancer tissues and is closely related to tumor metastasis and prognosis, and its role in tumor development is worth of further study.</description><identifier>ISSN: 1107-0625</identifier><identifier>PMID: 30358230</identifier><language>eng</language><publisher>Greece</publisher><ispartof>Journal of B.U. ON., 2018-07, Vol.23 (4), p.1185-1194</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30358230$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Huang, Hui</creatorcontrib><creatorcontrib>Li, Jing</creatorcontrib><creatorcontrib>Hu, Wen-Jia</creatorcontrib><creatorcontrib>Chen, Mei-Hui</creatorcontrib><creatorcontrib>Chen, Sha-Sha</creatorcontrib><creatorcontrib>Chen, Chen</creatorcontrib><creatorcontrib>Luo, Hai-Qing</creatorcontrib><creatorcontrib>Zhou, Ke-Yuan</creatorcontrib><creatorcontrib>Liu, Xin-Guang</creatorcontrib><creatorcontrib>Li, Xiang-Yong</creatorcontrib><title>Positive expression of chemokine (C-C Motif) ligand 18 and prognosis in cancer: A meta-analysis</title><title>Journal of B.U. ON.</title><addtitle>J BUON</addtitle><description>Chemokine (C-C Motif) Ligand 18 (CCL18) is a chemotactic cytokine involved in the pathogenesis and progression of various cancers by activating downstream signaling pathways and affecting cellular behaviors. We conducted a meta-analysis to evaluate the CCL18 as a prognostic marker for cancer and determine the relationship between CCL18 and clinicopathological features of cancer. We searched the PubMed, Cochrane, Embase, Web of Science and SinoMed databases for publications to investigate the association between CCL18 expression and survival outcome in cancer. Hazard ratios (HRs) and 95% confidence intervals (CI) of overall survival (OS) were pooled. Odds ratios (ORs) of clinicopathological features were computed. Meta-analysis was performed using STATA 12.0 software. Our meta-analysis identified a total of 17 studies including 2829 cases. Meta-analysis revealed that the expression of CCL18 in various cancer tissues was significantly higher than that in the normal group (OR=16.694, 95% CI=14.117-27.476, p&lt;0.01, random effects). The abnormal expression of CCL18 was associated with lymph node metastasis (OR=4.409, 95% CI=2.129-9.128, p&lt;0.01, random effects) and TNM stage (breast cancer subgroup: III+IV vs I+II OR=13.187, 95% CI=8.417-20.660, p&lt;0.01; gastric cancer subgroup: III+IV vs I+II OR=0.034, 95% CI=0.008-0.137, p&lt;0.01) but is was not related to gender (male vs. female: OR=0.88, 95% CI=0.667-1.162, p=0.368) and age (&gt;60 vs. ≤60 years: OR=1.118, 95% CI=0.795-1.571, p-0.522). CCL18 overexpression was associated with poor overall prognosis of breast cancer (Hazard Ratio/HR=2.969, 95% CI=1.361- 6.478, p&lt;0.01, random effects). CCL18 is highly expressed in cancer tissues and is closely related to tumor metastasis and prognosis, and its role in tumor development is worth of further study.</description><issn>1107-0625</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNo1kEtPwzAQhH0A0ar0LyAfyyGS7RDH5lZFvKQiOMA58mNdDIkd4gTRf48RZS-j0Xy7Ws0JWlJK6oJwVi3QOqV3kocTyqU4Q4uSlJVgJVmi9jkmP_kvwPA9jJCSjwFHh80b9PHDB8CbpmjwY5y8u8Sd36tgMRX4V4Yx7kNeT9gHbFQwMF7jLe5hUoUKqjvk6BydOtUlWB91hV5vb16a-2L3dPfQbHfFwCidCuCUaVk7ZxXjWvBaC01L55RjTmrqrKkEIcoSoEowwk02DCwVwCqZfblCm7-7-anPGdLU9j4Z6DoVIM6pZZRVTAp5JTJ6cURn3YNth9H3ajy0_6WUPy9jXLY</recordid><startdate>201807</startdate><enddate>201807</enddate><creator>Huang, Hui</creator><creator>Li, Jing</creator><creator>Hu, Wen-Jia</creator><creator>Chen, Mei-Hui</creator><creator>Chen, Sha-Sha</creator><creator>Chen, Chen</creator><creator>Luo, Hai-Qing</creator><creator>Zhou, Ke-Yuan</creator><creator>Liu, Xin-Guang</creator><creator>Li, Xiang-Yong</creator><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201807</creationdate><title>Positive expression of chemokine (C-C Motif) ligand 18 and prognosis in cancer: A meta-analysis</title><author>Huang, Hui ; Li, Jing ; Hu, Wen-Jia ; Chen, Mei-Hui ; Chen, Sha-Sha ; Chen, Chen ; Luo, Hai-Qing ; Zhou, Ke-Yuan ; Liu, Xin-Guang ; Li, Xiang-Yong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p211t-e612b97ffda26b867b8b13ffaf2f9b1fdc5800ad0e1a8206c00a2ed18e2592063</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Huang, Hui</creatorcontrib><creatorcontrib>Li, Jing</creatorcontrib><creatorcontrib>Hu, Wen-Jia</creatorcontrib><creatorcontrib>Chen, Mei-Hui</creatorcontrib><creatorcontrib>Chen, Sha-Sha</creatorcontrib><creatorcontrib>Chen, Chen</creatorcontrib><creatorcontrib>Luo, Hai-Qing</creatorcontrib><creatorcontrib>Zhou, Ke-Yuan</creatorcontrib><creatorcontrib>Liu, Xin-Guang</creatorcontrib><creatorcontrib>Li, Xiang-Yong</creatorcontrib><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of B.U. ON.</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Huang, Hui</au><au>Li, Jing</au><au>Hu, Wen-Jia</au><au>Chen, Mei-Hui</au><au>Chen, Sha-Sha</au><au>Chen, Chen</au><au>Luo, Hai-Qing</au><au>Zhou, Ke-Yuan</au><au>Liu, Xin-Guang</au><au>Li, Xiang-Yong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Positive expression of chemokine (C-C Motif) ligand 18 and prognosis in cancer: A meta-analysis</atitle><jtitle>Journal of B.U. ON.</jtitle><addtitle>J BUON</addtitle><date>2018-07</date><risdate>2018</risdate><volume>23</volume><issue>4</issue><spage>1185</spage><epage>1194</epage><pages>1185-1194</pages><issn>1107-0625</issn><abstract>Chemokine (C-C Motif) Ligand 18 (CCL18) is a chemotactic cytokine involved in the pathogenesis and progression of various cancers by activating downstream signaling pathways and affecting cellular behaviors. We conducted a meta-analysis to evaluate the CCL18 as a prognostic marker for cancer and determine the relationship between CCL18 and clinicopathological features of cancer. We searched the PubMed, Cochrane, Embase, Web of Science and SinoMed databases for publications to investigate the association between CCL18 expression and survival outcome in cancer. Hazard ratios (HRs) and 95% confidence intervals (CI) of overall survival (OS) were pooled. Odds ratios (ORs) of clinicopathological features were computed. Meta-analysis was performed using STATA 12.0 software. Our meta-analysis identified a total of 17 studies including 2829 cases. Meta-analysis revealed that the expression of CCL18 in various cancer tissues was significantly higher than that in the normal group (OR=16.694, 95% CI=14.117-27.476, p&lt;0.01, random effects). The abnormal expression of CCL18 was associated with lymph node metastasis (OR=4.409, 95% CI=2.129-9.128, p&lt;0.01, random effects) and TNM stage (breast cancer subgroup: III+IV vs I+II OR=13.187, 95% CI=8.417-20.660, p&lt;0.01; gastric cancer subgroup: III+IV vs I+II OR=0.034, 95% CI=0.008-0.137, p&lt;0.01) but is was not related to gender (male vs. female: OR=0.88, 95% CI=0.667-1.162, p=0.368) and age (&gt;60 vs. ≤60 years: OR=1.118, 95% CI=0.795-1.571, p-0.522). CCL18 overexpression was associated with poor overall prognosis of breast cancer (Hazard Ratio/HR=2.969, 95% CI=1.361- 6.478, p&lt;0.01, random effects). CCL18 is highly expressed in cancer tissues and is closely related to tumor metastasis and prognosis, and its role in tumor development is worth of further study.</abstract><cop>Greece</cop><pmid>30358230</pmid><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1107-0625
ispartof Journal of B.U. ON., 2018-07, Vol.23 (4), p.1185-1194
issn 1107-0625
language eng
recordid cdi_proquest_miscellaneous_2125298948
source EZB-FREE-00999 freely available EZB journals
title Positive expression of chemokine (C-C Motif) ligand 18 and prognosis in cancer: A meta-analysis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T13%3A32%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Positive%20expression%20of%20chemokine%20(C-C%20Motif)%20ligand%2018%20and%20prognosis%20in%20cancer:%20A%20meta-analysis&rft.jtitle=Journal%20of%20B.U.%20ON.&rft.au=Huang,%20Hui&rft.date=2018-07&rft.volume=23&rft.issue=4&rft.spage=1185&rft.epage=1194&rft.pages=1185-1194&rft.issn=1107-0625&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E2125298948%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2125298948&rft_id=info:pmid/30358230&rfr_iscdi=true